Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 16

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 16
---
 and MMSE between 27 and 22. During
the 6 month trial, patients received XPro or placebo once-a-week by subcutaneous injection. Two-thirds of the patients were randomized
to XPro. Overall, 56% and 44% of the 208 patients had mild AD and MCI, respectively.

XPro Registration Studies and/or Partnering

We plan to aggressively pursue
an efficient registration strategy using XPro to improve the lives of patients with ADi. We define ADi as Alzheimer’s disease with
biomarkers of inflammation. We believe ADi is not the only indication for XPro in neurodegenerative and neuropsychiatric diseases. We
plan to pursue other indications in neurodegenerative diseases as resources become available. We have received NIMH funding to support
a Phase II TRD program that will start patient enrollment during 2025. We have an active partnering position as it relates to XPro development
in neurodegenerative and neuropsychiatric diseases, although limited partnering discussions are underway at this time. There are two partnering
opportunities with this novel immunotherapy for the treatment of neurologic and psychiatric diseases. The first is a traditional partnership
focused on the developing the drug for all neurodegenerative and neuropsychiatric applications. The second is a more focused partnership
developing XPro as part of a combination therapy for a company’s existing therapy. After completion of proof-of-concept Phase II
studies, we will decide what the most efficient registration strategy is available to the company with XPro.

9

INKmune: Our NK cell Directed Product Candidate

INKmune is our product candidate that converts the patient’s resting
NK cells into cancer memory like NK cells, an essential step to allow them to participate in the immune control of the patient’s
cancer. We have shown this works ex vivo in human tissue cell cultures, and we believe that this will work in vivo which is the purpose
of our planned clinical trials.

Cancers grow and relapse because
they evade the immune system. In many cancers, NK cells are the most important cell for the elimination of residual disease that causes
cancer relapse. NK cells target cells based on a series of complex antigens on the cancer cell surface that signal the NK cells to activate
and kill the cancer cell. NK cells develop a memory like NK cell phenotype to enhance killing of cancer cells. This phenotype requires
multiple simultaneous signals to be delivered to the NK cells.